Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadershi... ( Broad Size Matrix of XIENCE PRIME to ...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position

Date:6/23/2009

Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter

ABBOTT PARK, Ill., June 23 /PRNewswire-FirstCall/ -- Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.

"XIENCE PRIME leverages and will build upon the outstanding body of clinical evidence from the SPIRIT family of clinical trials. The modified design features of the stent and delivery system are intended to make it easier for physicians to deliver the stent to the treatment area," said Robert Hance, senior vice president, vascular, Abbott. "As part of Abbott's leadership in drug eluting stents, we are committed to advancing treatment options and look forward to making the innovative XIENCE PRIME stent available to physicians and patients in Europe in the upcoming months."

XIENCE PRIME utilizes the same well-studied drug and proven biocompatible polymer as Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System. In addition, it offers a novel stent design and a modified delivery system designed for greater flexibility and improved deliverability. XIENCE PRIME uses cobalt chromium technology, which allows for very thin struts while maintaining strength to support the vessel as well as excellent visibility under X-ray during the stent implantation procedure. XIENCE PRIME is based upon the proven design of the MULTI-LINK(R) family of stents, which is the most widely used stent platform in the world - more than 2 million of Abbott's cobalt chromium stents have been implanted worldwide. Upon launch in Europe, XIENCE PRIME will be available in an expanded size matrix, including XIENCE PRIME SV for small vessels and XIENCE PRIME LL for long le
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition

Post Your Comments:

Breaking Medicine News(10 mins):Health News:IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care 2 Health News:IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care 3 Health News:Sticks and stones break bones, but this UH study may prevent it 2 Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 2 Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 3 Health News:Webcast Alert: MicroRNA: The Year in Review 2

[0] IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care [0] Sticks and stones break bones, but this UH study may prevent it [0] Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries [0] Webcast Alert: MicroRNA: The Year in Review [0] Oxycodone Linked to Rise in Opioid-Related Deaths

Global Med Technologies(R) to Present at Rodman & Renshaw 9th Annual Healthcare Conference Amira Pharmaceuticals Appoints First Vice President of Development Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track Study Shows Antibiotic Harms ALS Patients Exclusive American Council on Exercise (ACE) Research Study Proves Functional Fitness Really Works Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint

[0] Helix BioPharma Corp. Announces Fiscal Q1 2010 Results [0] Roper Industries Completes the Acquisition of Verathon, Inc.[0] Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities

Other Medicine Technology:For Iraq Veterans, Headaches Continue After Traumatic Brain Injury 2

For Iraq Veterans, Headaches Continue After Traumatic Brain Injury New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)

Medicine Products:

Baerveldt Glaucoma Implant Easyfield Octopus 101 Octopus 301

Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadershi...( Broad Size Matrix of XIENCE PRIME to ...),Health